KRAS G12D inhibitors continue to advance, but treatment resistance remains an important challenge. Understanding how that resistance develops is critical...

Metabolic dysfunction-associated steatohepatitis (MASH) remains a significant global health challenge, driven by a complex interplay of lipid dysregulation, inflammation, and...